PDGFRA and central nervous system cancer: Targeting the PDGFRA with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts [69], but, notably, there is more preclinical evidence linking PDGFR-β to glioma proliferation and survival than PDGFRA.